Back to search results

Study of LB-LR1109 for Advanced Solid Tumors and NSCLC

This study is testing a new treatment called LB-LR1109 for people with advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC), head and neck cancer, kidney cancer, bladder cancer, or melanoma. Some participants will receive LB-LR1109 alone, while others with NSCLC will receive LB-LR1109 combined with atezolizumab, another cancer drug. The main goals are to find the safest and most effective dose of LB-LR1109 and to understand its side effects. We are also looking for early signs of how well it works. You may be able to join if you are at least 18 years old and have one of these cancers.

Study design
This is an early-stage study (Phase 1a/1b) that is open-label, meaning everyone knows which treatment is being given. It is a dose-escalation study, meaning participants will receive increasing doses to find the best one. About 76 people are planned to join.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed through study completion, which is expected to be an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06332755

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

Recruiting
PHASE1Ages 18+InterventionalTreatment
LG Chem
~76 participants
Updated 2025-11-24 on ClinicalTrials.gov
What's tested:Phase 1a: LB-LR1109Phase 1b: LB-LR1109 and Atezolizumab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phase 1a: MTD and/or RP2D of LB-LR1109 as monotherapy in participants with advanced or metastatic solid tumors / Phase 1b: MTD and/or RP2D of LB-LR1109 as combination therapy with atezolizumab in participants with advanced or metastatic NSCLC
Measured over through study completion, an average of 1year
+1 more outcome measured

Conditions

Non-small Cell Lung Cancer(NSCLC)
Head and Neck Squamous Cell Carcinoma(HNSCC)
Renal Cell Carcinoma(RCC)
Urothelial Carcinoma
Malignant Melanoma

Explore related trials

Head and Neck Squamous Cell CarcinomaLung Non-Small Cell CarcinomaMelanomaRenal Cell CarcinomaSolid NeoplasmUrothelial Carcinomaactionable genomic alteration

Where it's being run

1 sites across 1 states
Virginia1

Who to contact

Alexander Spirra
[email protected]
(703)-783-4508
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Phase 1a: MTD and/or RP2D of LB-LR1109 as monotherapy in participants with advanced or metastatic solid tumors / Phase 1b: MTD and/or RP2D of LB-LR1109 as combination therapy with atezolizumab in participants with advanced or metastatic NSCLCthrough study completion, an average of 1year

    Number of participants with dose-limiting toxicities (DLTs)

  • Phase 1a: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as monotherapy / Phase 1b: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as combination therapy with atezolizumabthrough study completion, an average of 1year

    Incidence, severity (assessed by NCI CTCAE v5.0), and causality of AEs